Vita Golubovskaya
ProMab Biotechnologies. Inc
Dr. Vita Golubovskaya is a Director of Research and Business Development at Promab Biotechnologies leading research of novel anti-cancer immunotherapies including CAR-T cell therapy. She has more than 20 years of experience in cancer research, oncology and immunology. Previously, Dr. Golubovskaya was a Research Associate Professor at Roswell Park Cancer Institute and Research Professor at University of Buffalo, SUNY, Buffalo, NY. She holds Ph.D in Cell Biology from Institute of Cytology, St. Petersburg, Russia. Dr. Golubovskaya authored more than 80 publications, 20 patents and several book chapters. She was awarded Susan Komen Grant for Breast Cancer, NCI NIH and STTR grants. Dr. Golubovskaya served as a Guest Editor in Frontiers in Bioscience, Anti-Cancer Agents in Medicinal Chemistry and Cancers. She is an Active Member of AACR.
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.
Cancers Mar, 2016 | Pubmed ID: 26999211
FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells and .
Frontiers in bioscience (Landmark edition) 06, 2017 | Pubmed ID: 28410137
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.
Cancers Oct, 2017 | Pubmed ID: 29065481
CAR-T Cell Therapy: From the Bench to the Bedside.
Cancers Oct, 2017 | Pubmed ID: 29088081
GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
Frontiers in bioscience (Landmark edition) 06, 2018 | Pubmed ID: 29772559
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.
Cancers Sep, 2018 | Pubmed ID: 30208593
Generation of CAR-T Cells for Cancer Immunotherapy.
Methods in molecular biology (Clifton, N.J.) , 2019 | Pubmed ID: 30465215
Hypoxia Selectively Impairs CAR-T Cells In Vitro.
Cancers Apr, 2019 | Pubmed ID: 31052261
Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells and .
Frontiers in bioscience (Landmark edition) Jan, 2020 | Pubmed ID: 31585889
Major Highlights of the CAR-TCR Summit, Boston, 2016.
Anti-cancer agents in medicinal chemistry , 2017 | Pubmed ID: 28071584
DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.
Cancers Dec, 2019 | Pubmed ID: 31878090
PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.
Frontiers in bioscience (Landmark edition) Jun, 2020 | Pubmed ID: 32472757
Editorial On "Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy".
Vaccines Jul, 2020 | Pubmed ID: 32731435
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.
Cancers Feb, 2021 | Pubmed ID: 33652767
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
Biomedicines Oct, 2021 | Pubmed ID: 34680541
Editorial on Special Issue "Immunotherapy, Tumor Microenvironment and Survival Signaling".
Cancers Dec, 2021 | Pubmed ID: 35008254
CAR-T Cells Targeting Immune Checkpoint Pathway Players.
Frontiers in bioscience (Landmark edition) Apr, 2022 | Pubmed ID: 35468680
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.
Cancers May, 2022 | Pubmed ID: 35626122
Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers.
Frontiers in oncology , 2022 | Pubmed ID: 36353564
Cancer Immunotherapy: Where Next?
Cancers Apr, 2023 | Pubmed ID: 37190286
mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth.
Cancers May, 2023 | Pubmed ID: 37345198
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.
International journal of molecular sciences Aug, 2023 | Pubmed ID: 37686170
Editorial on "Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer".
Cancers Oct, 2023 | Pubmed ID: 37894420
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth.
Vaccines Jul, 2024 | Pubmed ID: 39066446
关于 JoVE
版权所属 © 2025 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。